Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 5/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.55 |
| ▸ | NAMPT | P43490 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13878303 | 0.91 | ALDH1A1 (0.64) | NAMPTALDH1A1GAALMNAEPHX2 | |
| SCHEMBL4247359 | 0.90 | CHRNA7 (0.56) | CHRNA7KCNH2NAMPTALDH1A1GAA | |
| SCHEMBL4242691 | 0.87 | CHRNA7 (0.56) | CHRNA7KCNH2NAMPTALDH1A1HTR3A | |
| SCHEMBL4238226 | 0.86 | CHRNA7 (0.56) | CHRNA7KCNH2NAMPTALDH1A1GAA | |
| SCHEMBL4245219 | 0.84 | HTR3A (0.57) | CHRNA7KCNH2NAMPTALDH1A1GAA | |
| SCHEMBL4383009 | 0.80 | BCL3 (0.66) | CHRNA7KCNH2NAMPTALDH1A1GAA | |
| SCHEMBL4394913 | 0.80 | ALDH1A1 (0.63) | NAMPTALDH1A1GAALMNAEPHX2 | |
| SCHEMBL4031580 | 0.79 | CHRNA7 (0.57) | CHRNA7KCNH2HTR3AEPHX2 | |
| SCHEMBL4386480 | 0.78 | GAA (0.68) | NAMPTALDH1A1GAALMNAEPHX2 | |
| SCHEMBL4241933 | 0.78 | CHRNA7 (0.58) | CHRNA7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| EP-2021331-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007138033-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA2 | CHRNA7 1/4885KCNH2 815/4885NAMPT 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.